Peripheral Vascular Devices – Market Insights – Japan

The Japanese PV device market will continue to experience modest growth through 2032 primarily due to growth in the endovascular procedure volumes along with the rising adoption of premium-priced devices such as DCBs and DES. However, revenue growth will be limited to some extent due to ASP declines caused by MHLW biennial reimbursement cuts over the forecast period.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for PV devices in Japan from 2019 through 2032.

Developments in endovascular interventions are focusing on treating the lower extremities.

What are the upcoming developments in the PV device market?

How are clinical developments across the globe impacting the Japanese PV device market?

Which new devices have launched or are expected to launch in the Japanese market?

The expansion of DES and DCB markets will be driven by new device launches and positive clinical data.

What are some ongoing and completed clinical trials that will contribute to the launch of new DES and DCB?

Will the emergence of DCBs have an impact on recently established DES usage?

To what degree will DCBs be adopted in Japan over the forecast period?

Which competitors are likely to enter the DCB market, and which will gain the most market share?

How does the Katsanos meta-analysis led to focus towards low dose paclitaxel coated balloons as well as sirolimus coated devices?

Will the emergence of DCBs have an impact on recently established DES usage?

Companies are following different strategies to succeed in the PV device market.

Which competitors are standing to gain market with the new devices, and how will it shape the market going forward?

What is the future outlook of current and new market players?

What are the device types and innovations behind the devices used to treat BTK lesions?

Table of contents